Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seng-Gee Lim

Showing results (191-200 of 219) with videos related to

Pageof 22
Sort By:
Frontiers in Immunology|October 5, 2020
CD4<sup>+</sup> T Cells Mediate the Development of Liver Fibrosis in High Fat Diet-Induced NAFLD in Humanized MiceZhisheng Her, Joel Heng Loong Tan, Yee-Siang Lim, et al.
Immunity|July 16, 2021
Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinomaYang Cheng, Bavani Gunasegaran, Harsimran D Singh, et al.
Hepatology (Baltimore, Md.)|March 11, 2021
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine PracticeHidenori Toyoda, Jennifer Leong, Charles Landis, et al.
Hepatology International|October 8, 2016
Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 updateGamal Shiha, Alaa Ibrahim, Ahmed Helmy, et al.
Nature Communications|March 28, 2020
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinomaLi Ren Kong, Nur Afiqah Binte Mohamed Salleh, Richard Weijie Ong, et al.
Gastroenterology|October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis BPatrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
The New England Journal of Medicine|November 8, 2022
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B InfectionMan-Fung Yuen, Seng-Gee Lim, Robert Plesniak, et al.
Journal of Hepatology|June 17, 2022
Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapyMan-Fung Yuen, Jeong Heo, Hiromitsu Kumada, et al.
Gut|June 4, 2025
Differential HCC risk among HBV indeterminate types at baseline and by phase transitionRui Huang, Huy N Trinh, Satoshi Yasuda, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2019
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 CountriesJin-Lin Hou, Wei Zhao, Changhyeong Lee, et al.
Pageof 22

Showing results (191-200 of 219) with videos related to

Sort By:
Pageof 22
Frontiers in Immunology|October 5, 2020
CD4<sup>+</sup> T Cells Mediate the Development of Liver Fibrosis in High Fat Diet-Induced NAFLD in Humanized MiceZhisheng Her, Joel Heng Loong Tan, Yee-Siang Lim, et al.
Immunity|July 16, 2021
Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinomaYang Cheng, Bavani Gunasegaran, Harsimran D Singh, et al.
Hepatology (Baltimore, Md.)|March 11, 2021
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine PracticeHidenori Toyoda, Jennifer Leong, Charles Landis, et al.
Hepatology International|October 8, 2016
Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 updateGamal Shiha, Alaa Ibrahim, Ahmed Helmy, et al.
Nature Communications|March 28, 2020
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinomaLi Ren Kong, Nur Afiqah Binte Mohamed Salleh, Richard Weijie Ong, et al.
Gastroenterology|October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis BPatrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
The New England Journal of Medicine|November 8, 2022
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B InfectionMan-Fung Yuen, Seng-Gee Lim, Robert Plesniak, et al.
Journal of Hepatology|June 17, 2022
Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapyMan-Fung Yuen, Jeong Heo, Hiromitsu Kumada, et al.
Gut|June 4, 2025
Differential HCC risk among HBV indeterminate types at baseline and by phase transitionRui Huang, Huy N Trinh, Satoshi Yasuda, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2019
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 CountriesJin-Lin Hou, Wei Zhao, Changhyeong Lee, et al.
Pageof 22